Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CpG 1018-adjuvanted pandemic influenza vaccine (H5N1)
- Development stage
- Unknown
- Lead developer
- Dynavax Technologies
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
CpG 1018-adjuvanted pandemic influenza vaccine (H5N1) is an investigational, monovalent H5N1 influenza vaccine program developed by Dynavax. It presents H5N1 hemagglutinin antigen to induce protective influenza-specific immunity and incorporates Dynavax's CpG 1018, a Toll-like receptor 9 agonist adjuvant intended to amplify innate and adaptive immune responses. Dynavax initiated the program as a pandemic-influenza proof of concept; Part 1 of its randomized Phase 1/2 study enrolled and dosed 101 adults aged 18–49 years in 2025, and a subsequent registered Phase 2 dose-finding study evaluates one- and two-dose intramuscular H5N1 hemagglutinin formulations containing CpG 1018, with some study arms also containing alum. ([biospace.com](https://www.biospace.com/press-releases/dynavax-reports-second-quarter-2025-financial-results))
- Other names
- CpG 1018-adjuvanted H5N1 vaccineCpG1018-adjuvanted H5N1 vaccineCpG-1018-adjuvanted H5N1 vaccineCpG 1018-adjuvanted pandemic influenza vaccine (H5N1)Pandemic Influenza H5N1 (CpG 1018-adjuvanted)Pandemic Influenza H5N1 Vaccine
02
Targets
TLR9 (Toll-like receptor 9)HA (Hemagglutinin)
Beyond the preview
Go deeper on CpG 1018-adjuvanted pandemic influenza vaccine (H5N1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CpG 1018-adjuvanted pandemic influenza vaccine (H5N1).